Phase ii study of bendamustine, bortezomib and dexamethasone as Second-Line treatment for elderly patients with multiple myeloma: The intergroupe francophone du myelome 2009-01 trial

Haematologica

Volumn 100, Issue 2, 2015, Pages e56-e59

  Rodon, Philippe ^a   Hulin, Cyrille ^b   Pegourie, Brigitte ^c   Tiab, Mourad ^d   Anglaret, Bruno ^e   Benboubker, Lotfi ^f   Jardel, Henry ^g   Decaux, Olivier ^h   Kolb, Brigitte ⁱ   Roussel, Murielle ^j   Garderet, Laurent ^k   Leleu, Xavier ^l   Fitoussi, Olivier ^m   Chaleteix, Carine ⁿ   Casassus, Philippe ^o   Lenain, Pascal ^p   Royer, Bruno ^q   Banos, Anne ^r   Benramdane, Riad ^s   Cony Makhoul, Pascale ^t   Dib, Mamoun ^u   Fontan, Jean ^v   Stoppa, Anne Marie ^w   Traullé, Catherine ^x   Vilque, Jean Pierre ^y   Pétillon, Marie Odile ^l   Mathiot, Claire ^z   Dejoie, Thomas ^aa   Avet Loiseau, Hervé ^j   Moreau, Philippe ^aa   more..

^a Hospital Center   (France)

^b UNIVERSITY HOSPITAL OF NANCY   (France)

^c GRENOBLE UNIVERSITY HOSPITAL   (France)

^d Medical Surgical Intensive Care Unit District Hospital Center   (France)

^e Hospital Center   (France)

^f UNIVERSITY HOSPITAL OF TOURS   (France)

^g Hospital Center   (France)

^h RENNES UNIVERSITY HOSPITAL   (France)

ⁱ REIMS UNIVERSITY HOSPITAL   (France)

^j TOULOUSE UNIVERSITY HOSPITAL   (France)

^k ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^l LILLE UNIVERSITY HOSPITAL   (France)

^m Polyclinique Nord Aquitaine   (France)

ⁿ UNIVERSITY HOSPITAL OF CLERMONT FERRAND   (France)

^o AVICENNE HOSPITAL   (France)

^p Centre de Lutte contre le Cancer Rouen   (France)

^q AMIENS UNIVERSITY HOSPITAL   (France)

^r Department of Nuclear Medicine Hospital   (France)

^s Regional Hospital Center   (France)

^t General Hospital   (France)

^u ANGERS UNIVERSITY HOSPITAL   (France)

^v UNIVERSITY HOSPITAL OF BESANÇON   (France)

^w INSTITUT PAOLI CALMETTES   (France)

^x Department of Functional Neurology and Epileptology   (France)

^y CENTRE FRANÇOIS BACLESSE   (France)

^z INSTITUT CURIE   (France)

^aa NANTES UNIVERSITY HOSPITAL   (France)

more..

Author keywords

Bendamustine; Elderly; Multiple myeloma; Relapse

Indexed keywords

BENDAMUSTINE; BETA 2 MICROGLOBULIN; BORTEZOMIB; CREATININE; DEXAMETHASONE; HEMOGLOBIN; ANTINEOPLASTIC AGENT; BORONIC ACID DERIVATIVE; CHLORMETHINE DERIVATIVE; PYRAZINE DERIVATIVE;

AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; DIARRHEA; FATIGUE; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; FOLLOW UP; HEART ARRHYTHMIA; HEART FAILURE; HUMAN; HYPERSENSITIVITY; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; NAUSEA AND VOMITING; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL (TOPIC); PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RELAPSE; THROMBOSIS; TREATMENT OUTCOME; TREATMENT RESPONSE; CANCER GRADING; CLINICAL TRIAL; MORTALITY; PATHOLOGY; PROGNOSIS; SURVIVAL RATE; TUMOR RECURRENCE; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BENDAMUSTINE HYDROCHLORIDE; BORONIC ACIDS; BORTEZOMIB; DEXAMETHASONE; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MULTIPLE MYELOMA; NEOPLASM GRADING; NEOPLASM RECURRENCE, LOCAL; NITROGEN MUSTARD COMPOUNDS; PROGNOSIS; PYRAZINES; SURVIVAL RATE;

EID: 84961291526     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2014.110890     Document Type: Article

References (12)

1. Fayers PM, Palumbo A, Hulin C, et al. Thalidomide for previously untreated elderly patients with multiple myeloma: meta-analysis of 1685 individual patient data from 6 randomized clinical trials. Blood. 2011;118(5):1239-1247.
2. San Miguel J F, Schlag R, Khuageva NK, et al. Bortezomib plus mel-phalan and prednisone for initial treatment of multiple myeloma. N Engl J Med. 2008;359(9):906-917.
3. Benboubker L, Dimopoulos M, Dispenzieri A, et al. Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma. N Engl J Med. 2014;371(10):906-917.
4. Dimopoulos M, Spencer A, Attal M, et al. Lenalidomide plus dexam-ethasone for relapsed or refractory multiple myeloma. N Engl J Med. 2007;357(21):2123-2132.
5. Jagannath S, Barlogie B, Berenson J, et al. A phase 2 study of two doses of bortezomib in relapsed and refractory multiple myeloma. Br J Haematol. 2004;127(2):165-172.
6. Damaj G, Malard F, Hulin C, et al. Efficacy of bendamustine in relapsed/refractory myeloma patients: Results from the French compassionate use program. Leuk Lymphoma. 2012;53(4):632-634.
7. Durie BGM, Harousseau JL, Miguel JS, et al. International uniform response criteria for multiple myeloma. Leukemia. 2006;20(12):1467-1473.
8. San Miguel J, Hungria VT, Yoon SS, et al. Panobinostat plus borte-zomib and dexamethasone versus placebo plus bortezomib and dex-amethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial. Lancet Oncol. 2014:15(11):1195-1206.
9. Lonial S, Kaufman JL. The era of combination therapy in myeloma. J Clin Oncol. 2012:30(20):2434-2436.
10. Ludwig H, Kasparu H, Leitgeb C, et al. Bendamustine-bortezomib-dexamethasone is an active and well tolerated regimen in patients with relapsed or refractory multiple myeloma. Blood. 2014; 123(7):985-991.
11. Offidani M, Corvatta L, Maracci L, et al. Efficacy and tolerability of bendamustine, bortezomib and dexamethasone in patients with relapsed-refractory multiple myeloma: a phase II study. Blood Cancer J. 2013;3.e162.
12. Lentzch S. Bendamustine: the remedy that came in from the cold. Blood. 2014;123(7):948-950.